Clinical trial

18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response

NCT04756921

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2018-09-01

PhaseN/A

Study timeline

Study start (actual)2018-09-01Date precision: day

Registry last updated2021-02-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HER2-positive Breast Cancerunresolved

Interventions

PyrotinibDRUG

Sponsors & collaborators

Biyun Wang, MDlead sponsor

Mapped research locations

ShanghaiShanghai Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04756921 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.